Targeting phosphoglycerate dehydrogenase in multiple myeloma

Targeting phosphoglycerate dehydrogenase in multiple myeloma

Abstract Background Multiple myeloma (MM) is a hematological malignancy characterized by the clonal expansion of plasma cells in the bone marrow. To date, this disease is still incurable and novel therapeutic approaches are required. Phosphoglycerate dehydrogenase (PHGDH) is the first and rate-limit...

Full description

Bibliographic Details
Main Authors: Samah Elsaadi, Ida Steiro, Pegah Abdollahi, Esten N. Vandsemb, Rui Yang, Tobias S. Slørdahl, Torstein Baade Rø, Eline Menu, Anne-Marit Sponaas, Magne Børset
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Experimental Hematology & Oncology
Subjects:
Myeloma
PHGDH
Serine
NCT-503
Bortezomib
Online Access:https://doi.org/10.1186/s40164-020-00196-w

Internet

https://doi.org/10.1186/s40164-020-00196-w

Similar Items